Search results
Showing 31 to 45 of 194 results for biopsy
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.
View recommendations for MTG72Show all sections
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over (NG36)
This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 and over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. It aims to reduce variation in practice and improve survival.
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)
This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatments are used.
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)
Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules
Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.
View quality statements for QS79Show all sections
Sections for QS79
- Quality statements
- Quality statement 1: Diagnosis of idiopathic pulmonary fibrosis
- Quality statement 2: Access to a specialist nurse
- Quality statement 3: Assessment for oxygen therapy
- Quality statement 4: Pulmonary rehabilitation
- Quality statement 5: Palliative care
- Update information
- About this quality standard
recommended to determine the impact of MRI fusion biopsy systems compared with cognitive fusion biopsy on the detection of...
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making